Breast Cancer News

News

Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC

05/30/2024

Grace Taylor, MS, MA

Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).

Merck announced that their phase...

05/30/2024

Journal of Clinical Pathways

News

Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review

05/15/2024

Grace Taylor, MS, MA

A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...

A systematic literature review...

05/15/2024

Journal of Clinical Pathways

News

The Economic Impact of Artificial Intelligence Usage in Screening Mammography

05/10/2024

Grace Taylor, MS, MA

Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.

Researchers evaluated the...

05/10/2024

Journal of Clinical Pathways

News

Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

01/16/2024

Stephanie Holland

Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.

Updated phase 1b results from...

01/16/2024

Oncology

News

Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis

12/06/2023

Edited by: Grace Taylor

Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...

Aditya Bardia, MD, and...

12/06/2023

Journal of Clinical Pathways

News

Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy

02/14/2023

Yvette C Terrie

The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...

The use of 5-fraction...

02/14/2023

Journal of Clinical Pathways

News

Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer

07/08/2022

Ellen Kurek

A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...

A panel of expert members of the...

07/08/2022

Journal of Clinical Pathways

News

Analyzing Experiences in Non-Medical Switching to Trastuzumab Biosimilars Among Oncologists and Patients With Breast Cancer

06/12/2022

Ellen Kurek

Study findings suggest that there is a need for tailored patient and oncologist information and education on trastuzumab biosimilars, as well as improved health care communication regarding switching.

Study findings suggest that...

06/12/2022

Journal of Clinical Pathways

News

Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy

06/09/2022

Ellen Kurek

A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.

A research group in Denmark...

06/09/2022

Journal of Clinical Pathways

News

Breast Conservation Yields Equal QOL Outcomes to Mastectomy and Reconstruction Among Patients With Breast Cancer

05/17/2022

Ellen Kurek

A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.

A comparative effectiveness...

05/17/2022

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Breast Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products